RayKnowChina Research Map
Shortlist

Blood disorders

Lymphoma in Beijing

北京 淋巴瘤

All diseases in Beijing

22 hospitals in Beijing

Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Beijing may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 83 papers led
  2. 83 papers led
  3. 74 papers led
  4. 37 papers led
  5. 36 papers led
  6. 35 papers led
  7. 31 papers led
  8. 30 papers led
    No open trial led
  9. 25 papers led
    No open trial led
  10. 24 papers led
  11. 14 papers led
  12. 7 papers led
    No open trial led
  13. 7 papers led
    No open trial led
  14. 6 papers led
    No open trial led
  15. 6 papers led
    No open trial led
  16. 4 papers led
    No open trial led
  17. 4 papers led
    No open trial led
  18. 2 papers led
    No open trial led
  19. 2 papers led
  20. 2 papers led
    No open trial led
  21. 0 papers led
    No open trial led
  22. 0 papers led

Lymphoma in every city Beijing on the disease page, with the national map

165

open trials on lymphoma with a hospital in Beijing

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Beijing as lead sponsor or study site. 76 of them are led by a hospital in Beijing. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07039474

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  2. Recruiting
    A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Phase
    Phase 4
    Started
    2026-03
    Posted
    Registry
    NCT07218341

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou

  3. Recruiting
    An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
    Phase
    Early phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07344818

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  4. Recruiting
    A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07377578

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Nanning

  5. Recruiting
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07409428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou

  6. Recruiting
    Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07441993

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou

  7. Recruiting
    A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07519772

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou

  8. Recruiting
    Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07523737

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  9. Recruiting
    Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07525466

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  10. Recruiting
    A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07562022

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  11. Recruiting
    A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07570823

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  12. Recruiting
    CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07587840

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  13. Recruiting
    JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07603479

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  14. Recruiting
    A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07606937

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin

  15. Recruiting
    Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07620314

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  16. Recruiting
    A Phase I Study of JLM019 Injection
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07623850

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  17. Recruiting
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07634471

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  18. Recruiting
    A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07661537

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou

  19. Recruiting
    In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07775508

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  20. Recruiting
    CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07779018

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  21. Recruiting
    A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07808827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  22. Recruiting
    Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07839247

    Age 70 years to Not stated (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  23. Recruiting
    Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07842835

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan

  24. Recruiting
    Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07851363

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  25. Recruiting
    Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07864701

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  26. Recruiting
    Prospective ctDNA Testing in Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07878351

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing

  27. Recruiting
    BEX101 in B-cell Non-Hodgkin's Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07882641

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  28. Recruiting
    Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07941063

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  29. Recruiting
    One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT06618313

    Age 18 years to Not stated (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  30. Recruiting
    A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06642792

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  31. Recruiting
    A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06697184

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Suzhou

  32. Recruiting
    A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06717347

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen

  33. Recruiting
    A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06742996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  34. Recruiting
    Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06760039

    Age 18 years to 80 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen University; 5 listed hospitals as study sitesBeijing, Fuzhou, Lanzhou, Nanchang, Zhanjiang, Zhuhai

  35. Recruiting
    A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06776952

    Age 18 days to 70 days (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  36. Recruiting
    Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06792253

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  37. Recruiting
    MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06793189

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 2 listed hospitals as study sitesBeijing, Shanghai, Shenyang

  38. Recruiting
    A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-01
    Posted
    Registry
    NCT06820268

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shijiazhuang, Wuhan

  39. Recruiting
    A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06822868

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  40. Recruiting
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06829771

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou

  41. Recruiting
    CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06834529

    Age 14 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  42. Recruiting
    Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT06838832

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  43. Recruiting
    Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06874946

    Age 3 years to 70 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  44. Recruiting
    Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
    Phase
    Phase 2/Phase 3
    Started
    2025-05
    Posted
    Registry
    NCT06895538

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  45. Recruiting
    A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06911502

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Jinan, Wuhan

  46. Recruiting
    CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06925464

    Age 14 years to 70 years (registered criteria)

    Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai

  47. Recruiting
    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06943872

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou

  48. Recruiting
    Zanubrutinib Combined With G-CVP in Previously Untreated FL
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06959732

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  49. Recruiting
    A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06973187

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou

  50. Recruiting
    A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT07000617

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing

  51. Recruiting
    BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07009002

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  52. Recruiting
    CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07022964

    Age 14 years to 70 years (registered criteria)

    Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai

  53. Recruiting
    DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07059650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou

  54. Recruiting
    A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07082686

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  55. Recruiting
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Early phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07093411

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad Hospital; 3 listed hospitals as study sitesBeijing, Hefei, Xi'an, Xuzhou

  56. Recruiting
    A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07124936

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou

  57. Recruiting
    GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07138547

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  58. Recruiting
    A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07154264

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou

  59. Recruiting
    Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
    Phase
    Phase 2/Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07185373

    Age 18 years to 75 years (registered criteria)

    Led by Huashan Hospital; 11 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai, Xi'an, Zhengzhou

  60. Recruiting
    PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07188610

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

  61. Recruiting
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07189065

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou

  62. Recruiting
    An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07200375

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou

  63. Recruiting
    Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07257510

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  64. Recruiting
    Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07321301

    Age 14 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  65. Recruiting
    Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07355699

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tongren Hospital; 2 listed hospitals as study sitesBeijing, Shenyang

  66. Recruiting
    Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07371923

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  67. Recruiting
    A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Early phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07376642

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Hangzhou

  68. Recruiting
    EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07450391

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  69. Recruiting
    Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07460362

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  70. Recruiting
    Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07489989

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  71. Recruiting
    Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07754890

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  72. Recruiting
    SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
    Phase
    Phase 3
    Started
    2024-02
    Posted
    Registry
    NCT06122389

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  73. Recruiting
    Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06176027

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  74. Recruiting
    A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06219356

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou

  75. Recruiting
    A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2024-03
    Posted
    Registry
    NCT06313957

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing, Zhengzhou

  76. Recruiting
    Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06321289

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  77. Recruiting
    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06323525

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  78. Recruiting
    A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06363994

    Age 60 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  79. Recruiting
    Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06376721

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  80. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

  81. Recruiting
    Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06393361

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  82. Recruiting
    A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06436677

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing

  83. Recruiting
    Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06445517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Tianjin

  84. Recruiting
    Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06454968

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  85. Recruiting
    Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06471738

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  86. Recruiting
    Glofitamab in Chinese Patients With R/R DLBCL
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06481826

    Age 18 years to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  87. Recruiting
    Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06484985

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai

  88. Recruiting
    Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06503263

    Age 14 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  89. Recruiting
    Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06521255

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou

  90. Recruiting
    Pola-ZR2P in Previously Untreated DLBCL
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06664411

    Age 14 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  91. Recruiting
    Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06733051

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteBeijing, Guangzhou

  92. Recruiting
    Golidocitinib Plus CHOP in Newly Diagnosed PTCL
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06739265

    Age 18 years to 70 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  93. Recruiting
    Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06824883

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  94. Recruiting
    Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06880913

    Age 12 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  95. Recruiting
    A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06971523

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  96. Recruiting
    ZR-MTX for PIOL Phase II Trial
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06973811

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  97. Recruiting
    Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT07155954

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  98. Recruiting
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT07234162

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  99. Recruiting
    Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma
    Phase
    N/A
    Started
    2024-07
    Posted
    Registry
    NCT07657494

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing

  100. Recruiting
    Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
    Phase
    Phase 1
    Started
    2023-07
    Posted
    Registry
    NCT05631886

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  101. Recruiting
    Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
    Phase
    Phase 1/Phase 2
    Started
    2023-08
    Posted
    Registry
    NCT05698147

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Hefei, Shanghai, Zhengzhou

  102. Recruiting
    A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT05800977

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou

  103. Recruiting
    A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
    Phase
    Phase 1/Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05806099

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  104. Recruiting
    Frontline of ASCT in High-risk DLBCL
    Phase
    Not given
    Started
    2023-05
    Posted
    Registry
    NCT05831865

    Age 18 years to 70 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  105. Recruiting
    Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
    Phase
    Phase 2
    Started
    2023-05
    Posted
    Registry
    NCT05833893

    Age 14 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  106. Recruiting
    CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT05948033

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  107. Recruiting
    TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06014073

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  108. Recruiting
    A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06066203

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  109. Recruiting
    Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06082102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou

  110. Recruiting
    A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT06084936

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou

  111. Recruiting
    A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06090539

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Nanchang

  112. Recruiting
    A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06136559

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou

  113. Recruiting
    A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06170489

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  114. Recruiting
    Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06176729

    Age 70 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  115. Recruiting
    Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
    Phase
    Phase 1
    Started
    2023-12
    Posted
    Registry
    NCT06180174

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  116. Recruiting
    Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06190067

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  117. Recruiting
    Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06876688

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou

  118. Recruiting
    A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Phase
    Phase 1
    Started
    2022-03
    Posted
    Registry
    NCT05091424

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Nanchang, Tianjin

  119. Recruiting
    A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
    Phase
    Phase 2/Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05139017

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou

  120. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  121. Recruiting
    Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
    Phase
    Phase 1/Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05294731

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  122. Recruiting
    A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
    Phase
    Phase 1/Phase 2
    Started
    2022-07
    Posted
    Registry
    NCT05487170

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  123. Recruiting
    A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT05498064

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  124. Recruiting
    A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
    Phase
    N/A
    Started
    2022-09
    Posted
    Registry
    NCT05514327

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  125. Recruiting
    TreAtments and outComes in paTients With prImary CutAneous Lymphoma
    Phase
    Not given
    Started
    2022-08
    Posted
    Registry
    NCT05518851

    Age not stated (registered criteria)

    Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Jinan

  126. Recruiting
    Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05554939

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  127. Recruiting
    A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05623982

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Qingdao

  128. Recruiting
    CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2022-01
    Posted
    Registry
    NCT06081478

    Age 14 years to 85 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  129. Recruiting
    Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
    Phase
    Phase 2
    Started
    2021-04
    Posted
    Registry
    NCT04728893

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  130. Recruiting
    A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2021-07
    Posted
    Registry
    NCT04993690

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou

  131. Recruiting
    First in Human, Dose Escalation Study of AN4005
    Phase
    Phase 1
    Started
    2021-09
    Posted
    Registry
    NCT04999384

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Harbin, Wuhan

  132. Recruiting
    A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT05006716

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou

  133. Recruiting
    A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
    Phase
    Phase 1
    Started
    2021-03
    Posted
    Registry
    NCT06189391

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou

  134. Recruiting
    Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    Phase
    Phase 2
    Started
    2020-01
    Posted
    Registry
    NCT03936153

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Lanzhou, Linyi, Shanghai, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou

  135. Recruiting
    Evaluate the Safety and Clinical Activity of HH2853
    Phase
    Phase 1/Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04390737

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou

  136. Recruiting
    Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
    Phase
    Phase 1/Phase 2
    Started
    2020-06
    Posted
    Registry
    NCT04440436

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  137. Recruiting
    Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 1/Phase 2
    Started
    2020-08
    Posted
    Registry
    NCT04494503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan

  138. Recruiting
    Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 2
    Started
    2020-10
    Posted
    Registry
    NCT04586478

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou

  139. Recruiting
    Phase Ib Clinical Study of Keynatinib
    Phase
    Phase 1
    Started
    2020-09
    Posted
    Registry
    NCT04807881

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Chengdu, Shanghai

  140. Recruiting
    China Lymphoma Patient Registry Study
    Phase
    Not given
    Started
    2017-05
    Posted
    Registry
    NCT03313271

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  141. Recruiting
    ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
    Phase
    Not given
    Started
    2016-10
    Posted
    Registry
    NCT02848274

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  142. Recruiting
    CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2014-10
    Posted
    Registry
    NCT02259556

    Age 16 years to 80 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  143. Recruiting
    Establishing Prospective Mediastinal Tumor Database of PUMCH
    Phase
    Not given
    Started
    2012-01
    Posted
    Registry
    NCT06421805

    Age not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  144. Recruiting
    Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
    Phase
    Phase 2/Phase 3
    Started
    2010-09
    Posted
    Registry
    NCT02657785

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  145. Recruiting
    Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
    Phase
    Phase 2/Phase 3
    Started
    2010-09
    Posted
    Registry
    NCT02836158

    Age 60 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  146. Not yet recruiting
    CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
    Phase
    Early phase 1
    Started
    2026-04
    Posted
    Registry
    NCT06986434

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  147. Not yet recruiting
    IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07355283

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  148. Not yet recruiting
    Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07554482

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  149. Not yet recruiting
    TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07639879

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  150. Not yet recruiting
    GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07670260

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  151. Not yet recruiting
    Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07717580

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  152. Not yet recruiting
    A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07758491

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  153. Not yet recruiting
    A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07784101

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  154. Not yet recruiting
    A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07854639

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  155. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  156. Not yet recruiting
    Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07917624

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  157. Not yet recruiting
    A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT06886139

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  158. Not yet recruiting
    JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07024147

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  159. Not yet recruiting
    A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07035379

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  160. Not yet recruiting
    Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07187960

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou

  161. Not yet recruiting
    A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06318884

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Zhengzhou

  162. Not yet recruiting
    A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06368167

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  163. Not yet recruiting
    Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06563778

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  164. Not yet recruiting
    Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06671717

    Age 18 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  165. Not yet recruiting
    Relmacabtagene Autoleucel in Hematologic Malignancies
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT06142188

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Beijing

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Beijing, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Aerospace Center Hospital航天中心医院nonenonenonenonenonenonenonenonenonenonenone111nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone332none0nonenonenonenonenonenone1nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Air Force General Hospital中国人民解放军空军特色医学中心nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing An Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Anding Hospital首都医科大学附属北京安定医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Anzhen Hospital首都医科大学附属北京安贞医院none6nonenonenonenonenonenonenonenonenone10nonenonenonenonenone2none0nonenonenonenonenone0nonenonenonenone19611 open805 opennonenone30none1nonenonenone0nonenone213nonenonenone1nonenonenonenonenonenonenonenonenonenone
Beijing Army General Hospital中国人民解放军总医院第七医学中心nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Boren Hospital北京高博博仁医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone01nonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Chao-Yang Hospital首都医科大学附属北京朝阳医院none81812662 open1821nonenonenone2601252nonenonenone20none00nonenonenonenonenonenonenone342 open340none3none13none1nonenonenonenone1none4nonenonenone321nonenonenone0nonenonenonenone
Beijing Chest Hospital首都医科大学附属北京胸科医院nonenonenonenone802 opennonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Children's Hospital首都医科大学附属北京儿童医院nonenonenonenonenonenonenonenone46none5none331 open4none49311 open251332012nonenone2none156241743nonenonenone100none11170nonenonenonenonenone131nonenonenone0nonenone
Beijing Daxing District People's Hospital北京市大兴区人民医院nonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Ditan Hospital, Capital Medical University首都医科大学附属北京地坛医院nonenone72nonenonenonenone50nonenonenonenonenonenonenonenonenonenone7nonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone1nonenonenonenonenonenonenonenonenonenonenonenone110nonenonenonenonenonenonenonenonenone
Beijing Friendship Hospital首都医科大学附属北京友谊医院none12511 open457 open3810401 opennone11none224711nonenone523 open30none0none0nonenone121none41 open4251 open0nonenone2none1nonenonenonenone1none1none02nonenone121 open4none0nonenonenonenonenonenonenone
Beijing Fuwai Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing GoBroad Hospital北京高博医院none01 open01 opennonenonenone01 opennonenonenonenonenonenonenonenone02 open04 opennonenone25 opennonenonenonenonenonenone01 open01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Haidian Hospital北京市海淀医院nonenonenonenone02 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Hospital北京医院nonenone151 open4741025nonenonenonenonenone01none2nonenonenone6none2none0none0none1141 opennonenone303 open3none01none8nonenonenonenonenone02none1nonenonenonenonenonenonenone0nonenonenonenonenonenone
Beijing Hospital, Capital Medical University北京市中西医结合医院nonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenone4nonenonenone11nonenonenonenonenonenonenonenonenone
Beijing Huairou Hospital北京怀柔医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing HuiLongGuan Hospital北京回龙观医院nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Jishuitan Hospital北京积水潭医院nonenonenonenonenonenonenonenonenonenone021nonenone16nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4none0nonenonenone0nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone
Beijing Jishuitan Hospital Guizhou Hospital北京积水潭医院贵州医院nonenonenonenonenonenonenonenonenonenone12nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Jishuitan Hospital Liaocheng Hospital北京积水潭医院聊城医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Lu Daopei Hospital北京道培医院nonenonenonenonenonenonenonenonenonenonenone1nonenone1none1none3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Luhe Hospital首都医科大学附属北京潞河医院nonenonenonenonenone7nonenonenone1none002nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenone
Beijing Rehabilitation Hospital首都医科大学附属北京康复医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Sanbo Brain Hospital北京三博脑科医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Shijitan Hospital北京世纪坛医院none191447none28130nonenone1none0nonenonenonenonenone400nonenonenonenonenonenonenonenonenonenonenonenonenone2nonenone1nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Stomatological Hospital首都医科大学附属北京口腔医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone5nonenonenonenonenonenonenonenonenonenonenone
Beijing Tiantan Hospital首都医科大学附属北京天坛医院nonenonenonenone18nonenone30712 opennonenone140none0nonenonenonenonenone242 opennone1nonenonenone342 opennone1609 opennonenone172 opennonenone61none2none40nonenone1nonenonenonenone0nonenonenonenonenonenonenonenone1nonenonenone
Beijing Tongren Hospital首都医科大学附属北京同仁医院61301534814none821none7none91601 opennone11 open357 opennone0nonenonenone736none3none45242 opennonenone1nonenonenonenonenonenone1none2nonenonenone2nonenone1none0none4nonenonenone
Beijing Tsinghua Changgung Hospital北京清华长庚医院nonenone29nonenone4none121002nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone8nonenone010none1none0nonenonenone10nonenonenonenone1nonenonenonenonenonenonenonenonenone
Beijing United Family Hospital北京和睦家医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenone
Beijing Youan Hospital, Capital Medical University首都医科大学附属北京佑安医院nonenone67nonenonenonenonenonenonenonenone1nonenonenonenonenonenone26nonenonenonenonenonenonenonenonenone5nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenone70nonenonenonenonenonenonenonenonenone
Beijng Anzhen Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College中国医学科学院肿瘤医院nonenonenonenone9none4nonenonenonenonenonenonenonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Capital Medical University Electric Teaching Hospital北京电力医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Capital Medical University Sanbo Brain Hospital北京三博脑科医院nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Hospital, Peking Union Medical College首都医科大学附属首都儿童医学中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenone2nonenonenonenone2nonenonenonenone0nonenonenone1nonenonenonenonenonenonenone23nonenonenonenonenonenonenone
China-Japan Friendship Hospital中日友好医院none5none13563 open9nonenonenonenonenone2nonenonenone2nonenone22nonenonenonenonenone60nonenonenonenone262 opennonenone001 opennone190none1100nonenone9nonenonenone10nonenonenonenone0nonenonenonenone
Chinese Medicine Affiliated Shenzhen Hospital北京中医药大学深圳医院(龙岗)nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Chinese Medicine Third Affiliated Hospital北京中医药大学第三附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Chinese PLA General Hospital中国人民解放军总医院8271846 open1406 open176712 open914 open561 open32none1271152 open06 open11 open21 open3730 open011nonenone122 open52 open4461 opennonenone765 open9110023120231601171 open1none02nonenonenonenonenone01nonenonenone
Civil Aviation General Hospital民航总医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Dongfang Hospital北京中医药大学东方医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone5nonenonenone1none5nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Dongzhimen Hospital北京中医药大学东直门医院nonenonenonenonenonenonenonenonenonenonenone0none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone7nonenonenonenonenone2none5nonenonenonenonenone14nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Dongzhimen Hospital北京中医药大学东直门医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fangshan Hospital, Beijing University of Chinese Medicine北京市房山区中医医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Jinzhou Medical University锦州医科大学附属第一医院none3none1932none218nonenonenone51nonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Hospital of Tsinghua University北京华信医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone10nonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Integrative Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fu Wai Hospital中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone340nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fu Wai Hospital中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone21 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fu Wai Hospital, Peking Union Medical College中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fuwai Hospital中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenone1none1nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone2432 open1503 opennonenone14nonenonenonenonenone21 opennonenone5nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
FuWai Hospital, Peking Union Medical Collegenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fuxing Hospital首都医科大学附属复兴医院nonenonenonenonenonenonenonenonenonenonenone1none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Guang Anmen Hospital中国中医科学院广安门医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guang'anmen Hospital中国中医科学院广安门医院nonenonenone91 open321 open10122 opennonenonenonenonenone1nonenonenonenonenonenonenone0nonenonenonenonenonenone3nonenonenone20none2nonenonenone1nonenonenonenonenonenonenonenone5nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Medical Sciences Fuwai Hospital中国医学科学院阜外医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
National Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院331 open18410 open1033 open1312 open58725 open452 open33335 open101 opennonenonenone8121nonenone3none832 open1nonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking Union Medical College Fuwai Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking Union Medical College Hospital北京协和医院341 open6510 open5421313 open2279 open10610 open521 opennone0none4671 open1272 open1161 open77410 open11711none8477 open69nonenone294 open16892 open327018144431 open212492 opennone51none14221 open321110nonenone0nonenone
Peking University Aerospace Center Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University Cancer Hospital北京大学肿瘤医院2826 open425 open2239 open16122 open342 open11614 opennonenonenonenone4121 open123nonenonenone834 opennonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University First Hospital北京大学第一医院nonenone202 open271 open535 open283 open444 opennone0nonenone41 open261175 opennonenone1366 opennone12nonenone153nonenonenone232 open571 open1114none21811128651 opennone0none01none15none1nonenonenonenone
Peking University International Hospital北大国际医院nonenonenonenonenonenonenonenone1nonenone00nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone6nonenonenone3nonenonenonenonenonenonenonenonenonenonenone2none1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University People's Hospital北京大学人民医院none2241 open213 open10214 open31 open4422 opennonenone06442 open102 opennone82 open195 open194 open293 open71 open146 opennone01 opennone42 open201 open121 open3nonenonenone1357none1none3nonenonenonenonenonenone51 opennone00none2700nonenonenone0nonenonenonenone
Peking University Shougang Hospital北京大学首钢医院nonenonenonenonenonenonenonenonenonenonenone11none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenone0nonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University Third Hospital北京大学第三医院nonenone121 open262 open514 open162 open282 open232 opennonenone6720070nonenone313 open01none0none22none2nonenone172 open541none102none522 open01 open1none10none1nonenonenone0nonenonenonenonenone0nonenonenonenone
Plastic Surgery Hospital中国医学科学院整形外科医院nonenonenonenonenonenone20nonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Plastic Surgery Hospital, Peking Union Medical Collegenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
PUMC Hospital中国医学科学院北京协和医院nonenonenonenonenone0nonenonenonenonenone00none0nonenone0nonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenone0nonenonenonenonenonenone0nonenonenonenonenonenonenonenone1nonenonenonenonenone
Sanbo Brain Hospital首都医科大学三博脑科医院nonenonenonenonenonenonenone301 opennonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sanbo Brain Hospital, Capital Medical Universitynonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Artillery General Hospital中国人民解放军火箭军特色医学中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shijitan Hospital, Captial Medical University首都医科大学附属北京世纪坛医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Wangjing Hospital中国中医科学院望京医院nonenonenonenonenonenonenonenonenonenonenone2nonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xiyuan Hospital中国中医科学院西苑医院nonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone25nonenonenonenonenone0none1nonenonenonenonenonenone9nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xuanwu Hospital首都医科大学宣武医院2none155262 open61225none071none3nonenone0nonenone71nonenone1none52 open2161 open7nonenone151 open5122 open96nonenonenone7nonenonenone10none2none1nonenonenonenonenonenonenonenonenonenonenonenone
Yuquan Hospital清华大学玉泉医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Beijing.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for lymphoma.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Beijing on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data